Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ArQule Signs c-Met Inhibitor, Discovery Platform Deals With Daiichi Sankyo

This article was originally published in PharmAsia News

Executive Summary

ArQule signed a two-part deal with Daiichi Sankyo Nov. 10 that gives the biotech important non-dilutive funding as well as validation for its discovery platform. In exchange for broad commercialization rights to ArQule's lead compound, the Phase II oncologic ARQ 197, Daiichi will pay $75 million in upfront funding along with up to $560 million in potential milestones

You may also be interested in...



Daiichi Sankyo And ArQule Expand Collaboration On Heels Of Positive ARQ 197 News

TOKYO - Daiichi Sankyo and ArQule announced a flurry of activity surrounding their oncology collaboration, including regulatory and clinical updates for c-Met inhibitor ARQ 197 and expansion of their drug discovery program based on ArQule kinase inhibitor platform (AKIP) technology

Daiichi Sankyo And ArQule Expand Collaboration On Heels Of Positive ARQ 197 News

TOKYO - Daiichi Sankyo and ArQule announced a flurry of activity surrounding their oncology collaboration, including regulatory and clinical updates for c-Met inhibitor ARQ 197 and expansion of their drug discovery program based on ArQule kinase inhibitor platform (AKIP) technology

Kyowa Hakko Kirin Pins Rebound On KW-0761 For Oncology And Allergy Indications

TOKYO - Kyowa Hakko Kirin posted modest gains in its pharmaceutical business at its announcement of interim results as expectation rides on the eventual outcome of KW-0761, a humanized anti-CCR-4 monoclonal antibody being developed by Kyowa for hematological cancer applications in Japan and the U.S. and by licensing partner Amgen in the U.K. for allergy application

UsernamePublicRestriction

Register

LL1122620

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel